KR102760315B1 - C/EBP 알파 saRNA 조성물 및 사용 방법 - Google Patents

C/EBP 알파 saRNA 조성물 및 사용 방법 Download PDF

Info

Publication number
KR102760315B1
KR102760315B1 KR1020237037891A KR20237037891A KR102760315B1 KR 102760315 B1 KR102760315 B1 KR 102760315B1 KR 1020237037891 A KR1020237037891 A KR 1020237037891A KR 20237037891 A KR20237037891 A KR 20237037891A KR 102760315 B1 KR102760315 B1 KR 102760315B1
Authority
KR
South Korea
Prior art keywords
delete delete
sarna
ebpα
gene
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020237037891A
Other languages
English (en)
Korean (ko)
Other versions
KR20230156961A (ko
Inventor
안드레아스 바그너
로버트 하빕
한스 이. 후버
폴 세트롬
엔드레 바켄 스토브네르
마르쿠스 호스바흐
모니카 크람퍼트
한스-페터 보른로커
Original Assignee
미나 테라퓨틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 미나 테라퓨틱스 리미티드 filed Critical 미나 테라퓨틱스 리미티드
Publication of KR20230156961A publication Critical patent/KR20230156961A/ko
Application granted granted Critical
Publication of KR102760315B1 publication Critical patent/KR102760315B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237037891A 2015-04-22 2016-04-21 C/EBP 알파 saRNA 조성물 및 사용 방법 Active KR102760315B1 (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562150889P 2015-04-22 2015-04-22
US62/150,889 2015-04-22
US201562235778P 2015-10-01 2015-10-01
US62/235,778 2015-10-01
US201662308521P 2016-03-15 2016-03-15
US62/308,521 2016-03-15
KR1020177030397A KR102599712B1 (ko) 2015-04-22 2016-04-21 C/EBP 알파 saRNA 조성물 및 사용 방법
PCT/GB2016/051117 WO2016170349A1 (en) 2015-04-22 2016-04-21 C/ebp alpha sarna compositions and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177030397A Division KR102599712B1 (ko) 2015-04-22 2016-04-21 C/EBP 알파 saRNA 조성물 및 사용 방법

Publications (2)

Publication Number Publication Date
KR20230156961A KR20230156961A (ko) 2023-11-15
KR102760315B1 true KR102760315B1 (ko) 2025-02-04

Family

ID=55948895

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237037891A Active KR102760315B1 (ko) 2015-04-22 2016-04-21 C/EBP 알파 saRNA 조성물 및 사용 방법
KR1020177030397A Active KR102599712B1 (ko) 2015-04-22 2016-04-21 C/EBP 알파 saRNA 조성물 및 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177030397A Active KR102599712B1 (ko) 2015-04-22 2016-04-21 C/EBP 알파 saRNA 조성물 및 사용 방법

Country Status (9)

Country Link
US (2) US10912790B2 (enExample)
EP (1) EP3286316A1 (enExample)
JP (4) JP6768701B2 (enExample)
KR (2) KR102760315B1 (enExample)
CN (2) CN108291228A (enExample)
AU (3) AU2016251415B9 (enExample)
CA (1) CA2980975A1 (enExample)
SG (1) SG11201707683YA (enExample)
WO (1) WO2016170349A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102507624B1 (ko) * 2013-11-22 2023-03-09 미나 테라퓨틱스 리미티드 Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
WO2018104538A1 (en) * 2016-12-08 2018-06-14 Curevac Ag Rna for treatment or prophylaxis of a liver disease
AU2018330495A1 (en) 2017-09-08 2020-03-26 Mina Therapeutics Limited Stabilized hnf4a sarna compositions and methods of use
EP3679140B1 (en) * 2017-09-08 2022-11-16 MiNA Therapeutics Limited Stabilized cebpa sarna compositions and methods of use
CN108103108A (zh) * 2018-01-30 2018-06-01 上海交通大学医学院附属瑞金医院 Cebpa基因缺失斑马鱼突变体的制备及其应用
EP3752165A1 (en) 2018-02-16 2020-12-23 Mina Therapeutics Limited C/ebp alpha sarna compositions and methods of use
CN110959042B (zh) * 2018-04-10 2022-10-18 中美瑞康核酸技术(南通)研究院有限公司 一种新型小激活rna
CA3102334A1 (en) * 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
EP4003423A4 (en) * 2019-07-26 2024-03-06 MiNA Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
EP4003060A4 (en) * 2019-07-29 2023-08-02 Brightseed, Inc. Method for improving digestive health
CN114585738A (zh) * 2019-09-20 2022-06-03 中美瑞康核酸技术(南通)研究院有限公司 用于治疗血小板减少症的核酸分子及其应用
EP4069848A4 (en) * 2019-12-03 2024-02-28 Merck Sharp & Dohme LLC IN VITRO CELL-BASED POWER DOSING
GB202019692D0 (en) * 2020-12-14 2021-01-27 Apterna Ltd Aptamer-sirna fusions
GB2618000A (en) 2020-12-28 2023-10-25 T Gjerde Douglas Temperature stable nucleic acid method for preparing vaccine
US20240301409A1 (en) * 2021-02-07 2024-09-12 Ractigen Therapeutics Chemically Modified Small Activating RNA
US20240207304A1 (en) 2021-04-28 2024-06-27 Mina Therapeutics Limited Combination Therapies Comprising C/EBP Alpha saRNA
KR102428121B1 (ko) * 2021-10-20 2022-08-08 주식회사 네오나 변형된 rt-let7을 유효성분으로 포함하는 간암의 예방 또는 치료를 위한 딜리버리 시스템
CN114306367B (zh) * 2021-08-27 2023-03-28 赵小洋 一种含有C/EBPα-saRNA的组合物
WO2024129571A1 (en) * 2022-12-12 2024-06-20 Regeneron Pharmaceuticals, Inc. Treatment of type 2 diabetes and/or chronic kidney disease with hepatocyte nuclear factor 4 alpha (hnf4a) agonists
WO2024134199A1 (en) * 2022-12-22 2024-06-27 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use
WO2024165876A2 (en) * 2023-02-10 2024-08-15 Mina Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
WO2024175887A1 (en) 2023-02-22 2024-08-29 Mina Therapeutics Limited Compositions and methods of using c/ebp alpha sarna
KR20240138691A (ko) * 2023-03-13 2024-09-20 부산대학교 산학협력단 류마티스 관절염 진단용 바이오마커 조성물, 이를 이용한 진단용 키트 및 이를 이용한 류마티스 관절염 진단방법
WO2025007024A1 (en) * 2023-06-29 2025-01-02 Repertoire Immune Medicines, Inc. Lipid particles for delivering a payload
WO2025052098A1 (en) 2023-09-08 2025-03-13 Mina Therapeutics Limited Tmem173 sarna compositions and methods of use
CN118480552B (zh) * 2024-01-18 2024-10-01 成都先衍生物技术有限公司 一种靶向CEBPA基因表达的saRNA及其用途
WO2025224036A1 (en) * 2024-04-22 2025-10-30 Mina Therapeutics Limited Chemically modified sarna compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175958A1 (en) 2011-06-21 2012-12-27 Mina Therapeutics Limited Albumin production and cell proliferation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2990410A1 (en) * 2004-08-10 2016-03-02 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
CA2743074A1 (en) * 2008-11-13 2010-05-20 Erasmus University Medical Center Rotterdam Efficient detection of double mutants of the cebpa gene in aml.
ES2629339T3 (es) * 2009-06-16 2017-08-08 Curna, Inc. Tratamiento de enfermedades relacionadas con la paraoxonasa 1 (pon1) por inhibición de transcrito antisentido natural a pon1
GB201010557D0 (en) * 2010-06-23 2010-08-11 Mina Therapeutics Ltd RNA molecules and uses thereof
DK2638163T3 (en) * 2010-11-12 2017-07-24 Massachusetts Gen Hospital POLYCOMB-ASSOCIATED NON-CODING RNAs
DE102011079572B4 (de) * 2011-07-21 2024-12-05 Endress+Hauser Conducta Gmbh+Co. Kg Gradiometer zur Bestimmung der elektrischen Leitfähigkeit eines in einem Behältnis enthaltenen Mediums
HK1214628A1 (zh) * 2012-11-05 2016-07-29 Pronai Therapeutics, Inc. 寡核苷酸癌症療法的給藥和施用
KR20150087270A (ko) * 2012-11-05 2015-07-29 프로나이 테라퓨틱스, 인코포레이티드 Bcl2 발현 조절에 의한 암치료용 바이오마커 이용 방법
WO2014078468A2 (en) * 2012-11-15 2014-05-22 Bristol-Myers Squibb Company Biomarkers for predicting clinical response of cancer patients to treatment with immunotherapeutic agent
KR102507624B1 (ko) * 2013-11-22 2023-03-09 미나 테라퓨틱스 리미티드 Ｃ/ｅｂｐ 알파 짧은 활성화 ｒｎａ 조성물 및 사용 방법
CN114224907A (zh) 2015-07-02 2022-03-25 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012175958A1 (en) 2011-06-21 2012-12-27 Mina Therapeutics Limited Albumin production and cell proliferation

Also Published As

Publication number Publication date
JP2024079713A (ja) 2024-06-11
CA2980975A1 (en) 2016-10-27
AU2016251415B2 (en) 2019-05-02
CN114525279A (zh) 2022-05-24
US20200376020A1 (en) 2020-12-03
US10912790B2 (en) 2021-02-09
JP2021192616A (ja) 2021-12-23
KR20230156961A (ko) 2023-11-15
EP3286316A1 (en) 2018-02-28
JP2018516545A (ja) 2018-06-28
AU2022202355A1 (en) 2022-04-28
KR20170136542A (ko) 2017-12-11
JP6768701B2 (ja) 2020-10-14
US20210187007A1 (en) 2021-06-24
AU2019210578A1 (en) 2019-08-22
AU2019210578B2 (en) 2022-01-13
AU2016251415B9 (en) 2019-05-23
WO2016170349A1 (en) 2016-10-27
JP2021000119A (ja) 2021-01-07
CN108291228A (zh) 2018-07-17
JP6931733B2 (ja) 2021-09-08
AU2016251415A1 (en) 2017-10-12
KR102599712B1 (ko) 2023-11-09
SG11201707683YA (en) 2017-11-29

Similar Documents

Publication Publication Date Title
JP6931733B2 (ja) Ｃ／ＥＢＰアルファｓａＲＮＡ組成物および使用方法
JP6621409B2 (ja) Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物
US11965163B2 (en) HNF4a saRNA compositions and methods of use
EP4219715A2 (en) Stabilized cebpa sarna compositions and methods of use
WO2024134199A1 (en) Chemically modified sarna compositions and methods of use
JP7525578B2 (ja) Ｃ／ＥＢＰα小分子活性化ＲＮＡ組成物

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231102

Application number text: 1020177030397

Filing date: 20171020

PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241107

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250122

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250123

End annual number: 3

Start annual number: 1

PG1601 Publication of registration